rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In the context of colorectal cancer, we present a method for constructing a surrogate biomarker that is able to predict with high accuracy whether a sample belongs to the "BRAF-positive" group, a high-risk group comprising V600E BRAF mutants and BRAF-mutant-like tumors.
|
28523274 |
2017 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
To understand how oncogenic B-Raf contributes to carcinogenesis, in particular to aspects other than cellular proliferation and survival, we generated three isogenic human colorectal carcinoma cell line models in which we can dynamically modulate the expression of the B-Raf(V600E) oncoprotein.
|
25381152 |
2015 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases.
|
28617917 |
2017 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer.
|
28416767 |
2017 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We have prospectively studied a series of 1624 consecutive colorectal carcinomas with an algorithm including immunohistochemical analysis of mismatch repair proteins and molecular study of microsatellite instability and BRAF c.1799 T > A (p.V600E) gene mutations.
|
24768606 |
2014 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test.
|
26588428 |
2016 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Thus, VE1 immunohistochemistry is a highly sensitive and specific method in detecting BRAF (V600E) mutations in colorectal carcinoma.
|
24085553 |
2013 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of hereditary non-polyposis colorectal cancer (Lynch's syndrome) and for the prediction of sensitivity to MEK inhibitors.
|
18428050 |
2008 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Somatic BRAF-V600E mutations in familial colorectal cancer.
|
17119056 |
2006 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The patient with SSL as index lesions who developed CRC harbored V600E BRAF mutation in both index lesion and the carcinoma.
|
25708741 |
2015 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although BRAF(V600E) mutation is associated with adverse clinical outcomes in patients with colorectal cancer (CRC), response and resistance mechanisms for therapeutic BRAF(V600E) inhibitors remains poorly understood.
|
26750638 |
2016 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients.
|
22899730 |
2012 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The V600E mutation does not appear to be associated with microsatellite instability, unlike the case in colorectal cancer.
|
22246856 |
2012 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was found in 15.6% of colorectal cancers but at higher frequencies in cancers with proximal location, poor differentiation and microsatellite instability (MSI) (all p < 0.001).
|
20233436 |
2010 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
|
25862899 |
2015 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although biased by the fact that germline testing was not pursued beyond direct sequencing in many cases lacking a high clinical index of suspicion of HNPCC, BRAF V600E detection was therefore considered to be 100% specific and 48% sensitive in detecting sporadic MSI-H CRC amongst those cases showing loss of MLH1 protein expression, in a population of patients with MSI-H CRC and clinical features suggestive of HNPCC.
|
17453358 |
2007 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
No point mutation was detected in BRAF codon Val600Glu for the studied CRC patients.
|
23297805 |
2013 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
|
25636897 |
2015 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients.
|
21587258 |
2011 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
However, the prognostic implications of BRAF V600E mutation and the associated clinicopathological characteristics in CRCs remain controversial.
|
27914130 |
2017 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Clinicopathological and molecular features can identify CRC patients with a higher prevalence of BRAF(V600E).
|
20635392 |
2011 |
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |